Hodges Capital Management’s ImmunityBio IBRX Stock Holding History

Hodges Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,000	Closed	-$76.7K	–	230
2026 Q1	$76.7K	Buy	+10,000	New	+$68.5K	0.01%	193

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hodges Capital Management's IBRX Position: Q2 2026 in Review

Hodges Capital Management sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 10,000 shares — an estimated $76.7K sold.

Hodges Capital Management first reported a position in IBRX in Q1 2026 and held it in 1 quarter. The position peaked at $76.7K in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Hodges Capital Management reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
Hodges Capital Management sold 10,000 ImmunityBio shares in Q2 2026, an estimated $76.7K.
Hodges Capital Management first reported a position in ImmunityBio in Q1 2026 and held it in 1 quarter.
Hodges Capital Management's ImmunityBio position peaked at $76.7K in Q1 2026.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Hodges Capital Management's 13F filing for Q2 2026, filed 3 Aug 2026.